Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 2/20 | 0.37 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.36 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12132845 | 1.00 | GRIN1 (0.37) | GRIN1GRIN2ACHRM2CHRM4CHRM5 | |
| SCHEMBL12132844 | 1.00 | GRIN1 (0.37) | GRIN1GRIN2ACHRM2CHRM4CHRM5 | |
| SCHEMBL12132799 | 0.91 | HTR1A (0.34) | GRIN1GRIN2AHTR1AADRA1DADRA1A | |
| SCHEMBL12132793 | 0.87 | GRIN1 (0.36) | GRIN1GRIN2ACHRM2CHRM4CHRM5 | |
| SCHEMBL12132792 | 0.87 | GRIN1 (0.36) | GRIN1GRIN2ACHRM2CHRM4CHRM5 | |
| SCHEMBL12662845 | 0.87 | GRIN1 (0.36) | GRIN1GRIN2ACHRM2CHRM4CHRM5 | |
| SCHEMBL12132821 | 0.87 | ADRA1A (0.36) | HTR1AADRA1DADRA1AADRA1B | |
| SCHEMBL1349974 | 0.87 | CYP3A4 (0.35) | — | |
| SCHEMBL12132772 | 0.87 | CYP3A4 (0.35) | — | |
| SCHEMBL12132837 | 0.87 | CYP3A4 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110288315-A1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE COMPOUND | DAISO CO., LTD. (JP) | 2011-11-24 | — | — | US | disclosed |
| US-20110288315-A1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE COMPOUND | DAISO CO., LTD. (JP) | 2011-11-24 | — | — | US | disclosed |
| EP-2325178-A1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE COMPOUND | DAISO CO., LTD. (JP) | 2011-05-25 | — | — | EP | disclosed |
| WO-2010013510-A1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE COMPOUND | ダイソー株式会社 (JP) | 2010-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288315-A1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE COMPOUND | CYP51A1, KMO, TALDO1 | GRIN1 2803/4885GRIN2A 3386/4885CHRM2 2189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.